Brief: Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission
10/05/2026 14:03
May 10 (Reuters) - MoonLake Immunotherapeutics MLTX.O: MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES POSITIVE OUTCOME FROM ITS FINAL PRE-BLA MEETING WITH THE U.S. FDA AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS MOONLAKE IMMUNOTHERAPEUTICS - FDA ACCEPTS MIRA AND VELA-TEEN TRIAL DATA FOR SONELKIMAB BLA SUBMISSION MOONLAKE IMMUNOTHERAPEUTICS - BLA SUBMISSION FOR SONELKIMAB IN HS PLANNED FOR END OF SEPTEMBER 2026 Source text: ID:nGNES9MB7 Further company coverage: MLTX.O ((Reuters.briefs@thomsonreuters.com;))
Recent news on MoonLake Immunotherapeutics
See all newsMoonLake jumps as AbbVie's weak skin drug data eases competition fears
Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial